文献速递淋巴瘤造血干细胞移植与细胞治疗

BV用于自体移植后复发难治霍奇金淋巴瘤的间接比较分析

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
PubMed 文献 · Br J Haematol · 2019-10-06

本研究通过文献间接治疗比较,评估维布妥昔单抗(BV)对比挽救化疗用于自体干细胞移植(ASCT)后复发或进展的经典型霍奇金淋巴瘤(cHL)的疗效。基于四个数据源的个体患者数据回顾性分析显示,BV作为首次挽救治疗在临床缓解和总生存方面均优于挽救化疗。

要点

  • BV较挽救化疗提高总缓解率22%。

核心结论

  • ASCT后复发或进展的cHL患者,BV作为首次挽救治疗可改善临床缓解和总生存。

研究设计与样本

  • 基于文献的间接治疗比较,采用四个数据源的个体患者数据回顾性分析。
  • 该比较效果研究旨在支持BV向澳大利亚药品福利咨询委员会提交的报销申请。

主要发现

  • BV较挽救化疗的总缓解率提高22%。

临床怎么用

  • 该保守分析结果可支持ASCT后复发cHL患者首次挽救治疗的临床管理和资助决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature-based analysis was undertaken to assess, via an indirect treatment comparison, the comparative efficacy of BV to salvage chemotherapy as treatment for R/R cHL patients following ASCT. This comparative effectiveness research was undertaken to support a reimbursement submission for BV to the Australian Pharmaceutical Benefits Advisory Committee. Retrospective analysis of individual patient data from four data sources demonstrated that the use of BV as first salvage treatment in cHL patients relapsing or progressing post-ASCT achieved improvements in both clinical response and overall survival. More specifically, BV was associated with an incremental improvement of 22% in overall response rate compared to salvage chemotherapy. Five-year overall survival and progression-free survival rates were 92·2% [95% confidence interval (CI): 85·5-99·3%] and 32·2% (95% CI: 19·1-54·6%) respectively for BV, compared to 30·5% (95% CI: 22·2-42·0%) and 3·2% (95% CI: 1·1-8·9%) respectively for salvage chemotherapy. The encouraging results from this conservative analysis have the potential to support informed clinical management and funding decisions for the first salvage of cHL patients demonstrating recurrence after ASCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kaloyannidis P, Hertzberg M, Webb K, et al. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Br J Haematol. 2019. PMID: 31588564. doi:10.1111/bjh.16201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。